This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: November 15, 2007
Last updated: November 1, 2016
Last verified: November 2016
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors. A first cohort of patients will receive the starting dose of 20mg/m2/day, once daily for 10 days in each 28 day cycle. Subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability and pharmacokinetic knowledge gained from prior treatment cohorts. The anticipated time on study treatment is until disease progression or intolerable toxicity.

Condition Intervention Phase
Neoplasms Drug: RO5045337 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Open-label, Phase I Study of Single Agent R7112 Administered Orally in Patients With Advanced Malignancies, Except All Forms of Leukaemia

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • MTD and associated dose schedule [ Time Frame: Every 28 days ]

Secondary Outcome Measures:
  • Clinical response [ Time Frame: Event driven ]
  • Dose-limiting toxicities. [ Time Frame: Throughout study ]
  • Pharmacokinetic profile [ Time Frame: Throughout study ]
  • Comparison safety and tolerability of daily versus twice daily dosing regimens [ Time Frame: approximately 18 months ]

Enrollment: 106
Study Start Date: December 2007
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: RO5045337
Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • solid tumor malignancies;
  • failed prior therapies, or no standard therapy available;
  • ECOG performance status of 0-2.

Exclusion Criteria:

  • patients receiving any other agent or therapy to treat their malignancy;
  • pre-existing gastrointestinal disorders which may interfere with absorption of drugs;
  • clinically significant cardiovascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00559533

United States, Colorado
Aurora, Colorado, United States, 80045
United States, Massachusetts
Boston, Massachusetts, United States, 02115
United States, New York
New York, New York, United States, 10065
United States, Texas
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 98229
Bordeaux, France, 33076
Lyon, France, 69373
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00559533     History of Changes
Other Study ID Numbers: NO21280
Study First Received: November 15, 2007
Last Updated: November 1, 2016 processed this record on August 21, 2017